Physician profile
Kyle Greene
NPI 1033470364
$5,886.27
in general payments reported to CMS, 2019-2025
51 companies · $93.55 in 2025
The $93.55 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,072 · 2020: $1,170 · 2021: $89.42 · 2022: $63.04 · 2023: $310 · 2024: $89.09 · 2025: $93.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.99 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $469.35 | 2019-2022 | |
| Genentech USA, INC. | $370.43 | 2019-2020 | |
| Incyte Corporation | $300.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $272.42 | 2019-2025 | Enhertu, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $272.15 | 2019-2025 | |
| Amgen INC. | $270.34 | 2019-2020 | |
| Lilly USA, LLC | $255.84 | 2019-2023 | Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $247.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $232.44 | 2019-2020 | |
| Celgene Corporation | $210.23 | 2019-2020 | |
| Abbvie INC. | $208.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.40 | 2019-2020 | |
| Eisai INC. | $199.07 | 2019-2020 | |
| Exelixis INC. | $158.44 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.